The articles brought together here explore consumer benefits and their price—whether financial, practical, or potentially medical. Apple and Nintendo are offering seasonal deals, but in different ways: instead of cutting prices, Apple gives customers a gift card for future purchases, while Nintendo lowers the price of select controllers. Against this backdrop, an article about drugs for diabetes and obesity points to a more serious principle: an attractive effect cannot be assessed separately from its limitations and possible side effects. Together, these pieces show why it is important to look beyond the promised benefit and consider the terms, evidence, and who will actually receive it.
Both retail stories focus on attracting shoppers with limited-time holiday offers. But “discount” does not quite describe Apple’s promotion. The company does not reduce the price of a device directly; customers receive a gift card that can be used later for Apple products, software, and subscriptions. So the value of the deal depends on whether someone plans to make another purchase within Apple’s ecosystem.
According to 9to5Mac’s coverage of Apple’s promotion, the largest gift card is worth $300—$50 more than in previous years. The biggest reward comes with the purchase of a 16-inch MacBook Pro with an M5 Pro or M5 Max chip. Buying a MacBook Air earns a $200 card, while a Mac mini comes with a $100 card. The rewards are smaller for phones: $50 for an iPhone 17e, $75 for an iPhone 16 or iPhone 17, and $100 for an iPhone Air. The promotion also covers select iPad, Apple Watch, AirPods, HomePod, Beats, and accessory models.
This does not mean customers save the corresponding amount when paying for the device. The gift card does not lower the upfront price and is useful only if the customer makes a later purchase from Apple. Some of the latest devices are also excluded from the offer. The promotion is scheduled to run from November 27 through November 30, 2026, online and at Apple stores. This format benefits the company not only by stimulating sales but also by keeping customers within its product range, directing their future spending toward its own devices and services.
Nintendo, by contrast, is offering direct price cuts on selected accessories in its European store. According to Nintendo Life, a two-pack of NES controllers is selling for £34.99, while the Mega Drive and N64 controllers are each priced at £27.99. The GameCube controller for Switch 2 has been reduced to £41.29. Classic Joy-Con 2 controllers are also discounted, to £52.49.
Access to these deals is limited, however: the controllers are available only through Nintendo’s official store and only to paid Nintendo Switch Online members. Customers must sign in to their accounts, and stock may run out quickly. The SNES controller has already sold out. So while the savings are more straightforward than Apple’s, the offer is restricted by membership and availability. The discount thus serves not only to clear stock, but also to encourage subscriptions and activity on Nintendo’s own platform.
The third article shifts the discussion from retail to medical promises and how they are tested. A ScienceDaily review examines drugs based on semaglutide and tirzepatide, used to treat obesity and type 2 diabetes. Researchers looked at evidence on the possible effects of these drugs on the brain, memory, and thinking. The findings are mixed so far: animal studies point to possible effects on learning and memory, while an analysis of medical records links use of the drugs to a lower risk of dementia among people with type 2 diabetes. But observational data cannot prove that the drugs themselves caused the lower risk.
More rigorous testing has also offered no grounds for broad claims. In the EVOKE and EVOKE+ trials, semaglutide did not slow the progression of early Alzheimer’s disease. Although some disease-related biomarkers changed, this did not lead to a measurable improvement in the clinical course of the disease. It is important to distinguish an effect on an individual biological marker from proven benefit to patients: the former does not, by itself, mean the disease progresses more slowly or that memory is preserved.
The review’s authors suggest that the drugs may still matter for some people, though perhaps not by directly treating neurodegeneration. Obesity and diabetes can be associated with difficulties in attention, planning, and processing speed; these problems may reflect metabolic issues and vascular health. Improving blood sugar control, metabolism, and vascular health could theoretically help preserve cognitive function, particularly if treatment begins before significant impairment develops. The review’s first author, Stina Börchers, stresses the need to find out “whether these treatments can help people with obesity or diabetes preserve cognitive abilities” and which patients might benefit.
At the same time, potential benefits cannot be considered apart from the risks. In older and physically frail people, rapid weight loss may be accompanied by loss of muscle mass and reduced strength and physical function. So the question is not simply whether a drug “acts on the brain”: researchers need to understand how it works, identify the groups for whom treatment is appropriate, and assess the balance of benefits and harms. They call for clinical trials that measure memory, attention, and other cognitive abilities from the start of treatment and track them over time.
The common lesson in these articles is that the value of a benefit depends on its terms and on how it is measured. Apple’s gift card is valuable only to people who plan to spend more later; Nintendo’s discount is available to subscribers and limited by stock; and the potential medical benefits of these drugs require confirmation in clinical trials and may come with unwanted consequences. In consumer deals, it is important to distinguish an actual price reduction from credit toward a future purchase; in medicine, to distinguish a preliminary association or biological effect from a proven improvement in health. In all three cases, an attractive promise matters only once we understand whom it is for, how it works, and what it costs.